BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36389724)

  • 1. Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy.
    Qiao W; Wang Q; Hu C; Zhang Y; Li J; Sun Y; Yuan C; Wang W; Liu B; Zhang Y
    Front Immunol; 2022; 13():1019772. PubMed ID: 36389724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of adjuvant transcatheter arterial chemoembolization following repeated curative resection/ablation for hepatocellular carcinoma with early recurrence: a propensity score matching analysis.
    Huang K; Qian T; Chen W; Lao M; Li H; Lin WC; Chen BW; Bai X; Gao S; Ma T; Liang T
    BMC Cancer; 2024 May; 24(1):620. PubMed ID: 38773564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
    World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
    Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy.
    Ye TW; Wang DD; Lu WF; Xie YM; Xu FQ; Fu TW; Zhang KJ; Liu SY; Xie GL; Cheng J; Jiang K; Xiao ZQ; Yao WF; Shen GL; Liu JW; Huang DS; Zhang CW; Liang L
    Expert Rev Gastroenterol Hepatol; 2023 Apr; 17(4):395-403. PubMed ID: 36939280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.
    Li C; Wang MD; Lu L; Wu H; Yu JJ; Zhang WG; Pawlik TM; Zhang YM; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Xing H; Li ZL; Lau WY; Wu MC; Shen F; Yang T
    Hepatol Int; 2019 Nov; 13(6):736-747. PubMed ID: 31486964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance.
    Shi Q; Zhou X; Zhang Z; Zhang W; Ma J; Yang M; Yu J; Luo J; Liu L; Yan Z
    Front Immunol; 2022; 13():1097625. PubMed ID: 36703965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona clinic liver cancer Stage B hepatocellular carcinoma: A propensity score matching study.
    Li X; Chen B; An C; Cheng Z; Han Z; Liu F; Yu J; Liang P
    J Cancer Res Ther; 2020 Sep; 16(5):1027-1037. PubMed ID: 33004744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of traditional herbal medicine versus transcatheter arterial chemoembolization in postsurgical patients with hepatocellular carcinoma: A retrospective study.
    Xu X; Chen R; Chen Q; An K; Ding L; Zhang L; Wang F; Deng Y
    Complement Ther Clin Pract; 2021 May; 43():101359. PubMed ID: 33711747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
    Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
    Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE.
    Bai S; Yang P; Liu J; Xue H; Xia Y; Liu F; Yang Z; Zhang L; Wu Y; Shen F; Wang K
    Oncologist; 2023 Aug; 28(8):e633-e644. PubMed ID: 37029989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cidan Capsule in Combination with Adjuvant Transarterial Chemoembolization Reduces Recurrence Rate after Curative Resection of Hepatocellular Carcinoma: A Multicenter, Randomized Controlled Trial.
    Zheng DH; Yang JM; Wu JX; Cheng SQ; Zhang SG; Wu D; Li AJ; Fu XH; Li X; Qi FC; Duan WH; Chen JH; Yang ZY; Liang L; Zeng JX; Zheng WD; Wu MC
    Chin J Integr Med; 2023 Jan; 29(1):3-9. PubMed ID: 35915317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
    Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
    BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy.
    Chen W; Hu S; Liu Z; Sun Y; Wu J; Shen S; Peng Z
    Hepatol Int; 2023 Apr; 17(2):406-416. PubMed ID: 36645648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal treatment strategy for recurrent hepatocellular carcinoma based on recurrence time and tumor size: A propensity score matching study.
    Wan W; Zhang H; Ji T; Zhang L; Luo K; Xiong D
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102157. PubMed ID: 37321321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial Chemoembolization Plus Tyrosinkinase Inhibitors and PD-1 Inhibitors for Spontaneously Ruptured Hepatocellular Carcinoma.
    Ji J; Zhou C; Yan LL; Ma Y; Xu C; Wang FA; Zhou WZ; Lv PH
    Cardiovasc Intervent Radiol; 2024 Mar; 47(3):299-309. PubMed ID: 38291158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study.
    Wang Z; Ren Z; Chen Y; Hu J; Yang G; Yu L; Yang X; Huang A; Zhang X; Zhou S; Sun H; Wang Y; Ge N; Xu X; Tang Z; Lau W; Fan J; Wang J; Zhou J
    Clin Cancer Res; 2018 May; 24(9):2074-2081. PubMed ID: 29420221
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma.
    Men B; Cui H; Han Z; Jin X; Xu Q; Jin Y; Piao Z; Zhang S
    Front Immunol; 2024; 15():1337396. PubMed ID: 38380330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.